Reimbursement Past Sema denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for reimbursement past sema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Classifies Past Semaglutide Use as Experimental for Reimbursement Purposes

An "experimental or investigational" denial for a past semaglutide claim is one of the more unusual denials in this category, because semaglutide has FDA approval for clearly defined indications. When Aetna issues this denial for a retrospective reimbursement claim, it almost always reflects one of three scenarios: (1) the specific indication documented on the claim did not match an FDA-approved label indication at the time of service; (2) the claim was for an off-label use (e.g., a pediatric population, an unapproved indication, or a dosing regimen not described in the label); or (3) the plan's clinical policy restricted the drug's covered indications more narrowly than the FDA label, and the documentation did not establish that the patient met the narrower coverage criteria.

## Why This Denial Is Contestable

For on-label FDA-approved use, an "experimental" denial is very difficult for Aetna to sustain on external review. The IRO applies an independent evidence standard, and FDA approval for the documented indication is strong — often dispositive — evidence that a drug is not investigational. For off-label use, the analysis is more complex, but professional society guidelines endorsing the off-label application for the patient's documented condition are recognized rebuttal evidence under most state external-review laws.

## Federal Appeal Framework

• Internal appeal: File within 180 days. Request Aetna's written clinical policy document for semaglutide and the specific evidence criteria used to classify the use as investigational. Compare those criteria against the FDA-approved prescribing label in effect at the time of service.
• External review (ACA §2719): Mandatory option after internal exhaustion, within approximately four months of final denial. IROs have consistently overturned "experimental" denials for FDA-approved on-label use. Turnaround is 45 days standard, 72 hours for urgent cases.
• ERISA §503: Full-and-fair review rights apply to self-funded employer plans.

## Documentation to Gather

1. FDA prescribing label in effect at the time of service — obtain the current label from the FDA's DailyMed database and confirm that the documented indication falls within the approved indications section. Your prescriber or pharmacist can assist. 2. Prescriber's clinical records — diagnosis code, clinical notes, and a letter confirming the indication for which semaglutide was prescribed, mapped explicitly to an FDA-approved indication. 3. Aetna's clinical policy document — request the exact version in effect at the time of service to compare its coverage criteria against the FDA label. 4. Relevant specialty-society guidelines (for off-label use) — if the use was off-label, ask your clinician to identify the applicable guideline from the relevant specialty organization. 5. Pharmacy records — confirming the product dispensed and the prescribing diagnosis.

## Criteria-Mapping Structure

For each element of Aetna's "experimental" classification, present the FDA label section (or guideline reference) that directly rebuts it. If the denial rests on a plan-policy restriction narrower than the FDA label, make that discordance explicit — IROs treat plan policies that are more restrictive than the FDA label with skepticism.